martes, 6 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· October 31, 2025

Chevron Reports Third Quarter 2025 Results

View original at finance.yahoo.com
Chevron Reports Third Quarter 2025 Results Reported earnings of $3.5 billion; adjusted earnings of $3.6 billion Record production of 4.1 million BOE per day; 21 percent higher than last year Cash flow from operations of $9.4 billion; adjusted free cash flow of $7.0 billion HOUSTON, October 31, 2025--(BUSINESS WIRE)--Ch…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • U.S. and worldwide production hit new company records, up 27 percent and 21 percent, respectively, from last year

    80% confidence

  • The company returned $6 billion of cash to shareholders in the quarter, and over $78 billion in the last 3 years

    80% confidence

  • Third quarter results reflect record production, strong cash generation and sustained superior cash returns to shareholders

    80% confidence

  • The integration of Hess is progressing well, unlocking synergies across our operations and positioning Chevron as a premier global energy company

    80% confidence

  • Strong cash flow from operations was sustained while the company's adjusted free cash flow increased more than 50 percent from a year ago

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Chevron Reports Third Quarter 2025 Results — Source | Via News | es.VIA.NEWS